| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0889-8588(05)70232-X |
| P698 | PubMed publication ID | 11525297 |
| P2093 | author name string | M R Smith | |
| P2860 | cites work | A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma | Q28370338 |
| Treatment of painful prostatic bone metastases with oral etidronate disodium | Q30457578 | ||
| Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review | Q31973506 | ||
| Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis | Q33585579 | ||
| Saw palmetto for the treatment of men with lower urinary tract symptoms | Q33883774 | ||
| Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer | Q33897875 | ||
| A systematic review of newer pharmacotherapies for depression in adults: evidence report summary | Q33902017 | ||
| Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitors | Q34296942 | ||
| Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens | Q36684590 | ||
| Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. | Q36868030 | ||
| PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer | Q39432424 | ||
| Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the finnish prostate cancer group | Q39497802 | ||
| Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer | Q39505334 | ||
| Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients | Q40921601 | ||
| Androgens, brain, and behavior | Q41014045 | ||
| Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma | Q41347991 | ||
| Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells | Q41482572 | ||
| PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo . | Q41714789 | ||
| Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review | Q41723658 | ||
| Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study | Q42383384 | ||
| Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years | Q42674269 | ||
| Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study | Q43685121 | ||
| A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer | Q47918737 | ||
| A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. | Q51095285 | ||
| Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. | Q51607270 | ||
| Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. | Q53537253 | ||
| Megestrol Acetate for the Prevention of Hot Flashes | Q56690205 | ||
| Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials | Q57407566 | ||
| Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma | Q57905146 | ||
| Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer | Q67465852 | ||
| Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer | Q67543692 | ||
| Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates | Q67559778 | ||
| Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells | Q69977844 | ||
| Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group | Q71890854 | ||
| Binding of permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate | Q72728677 | ||
| Progressive osteoporosis during androgen deprivation therapy for prostate cancer | Q73288056 | ||
| Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin | Q73376868 | ||
| Transdermal estrogen in the treatment of hot flushes in men with prostate cancer | Q73401221 | ||
| Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial | Q73492614 | ||
| Treatment of postmenopausal osteoporosis | Q74288827 | ||
| Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression | Q74446178 | ||
| Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton | Q74472410 | ||
| Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes | Q74519493 | ||
| A review of the effectiveness of Cimicifuga racemosa (black cohosh) for the symptoms of menopause | Q74741894 | ||
| Reduction in new metastases in breast cancer with adjuvant clodronate treatment | Q74837359 | ||
| Bisphosphonates as anticancer drugs | Q74837390 | ||
| Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer | Q77300267 | ||
| The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy | Q77442914 | ||
| Current use of bisphosphonates in oncology. International Bone and Cancer Study Group | Q77669938 | ||
| Testosterone and depression in aging men | Q77907228 | ||
| Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer | Q77914351 | ||
| P433 | issue | 3 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 559-571 | |
| P577 | publication date | 2001-06-01 | |
| P1433 | published in | Hematology / Oncology Clinics of North America | Q15749192 |
| P1476 | title | Complementary and alternative therapies for advanced prostate cancer | |
| P478 | volume | 15 |
| Q37105407 | Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management |
| Q34143921 | Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health‐related quality of life benefits for osteoporotic men with prostate cancer |
| Q35204620 | Early prostate cancer: prevention, treatment modalities, and quality of life issues. |
| Q36432836 | Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer |
| Q36896020 | The role of intermittent androgen deprivation in prostate cancer |
| Q37493951 | The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network |
| Q36432832 | Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer |
| Q34270813 | Venlafaxine Hydrochloride for the Treatment of Hot Flashes |
Search more.